Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1938222 Target Snapshot

1-phosphatidylinositol 3-phosphate 5-kinase · SINGLE PROTEIN · Homo sapiens

262Compounds
97Assays
0Approved Drugs
175.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

1-phosphatidylinositol 3-phosphate 5-kinase shows clinical signal disease relevance led by Crohn's disease. 3 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9Y2I7. Start with Crohn's disease, then reuse UniProt Q9Y2I7 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Crohn's disease, then reuse UniProt Q9Y2I7 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
Crohn's disease

1-phosphatidylinositol 3-phosphate 5-kinase shows clinical signal disease relevance led by Crohn's disease. 3 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with Crohn's disease because it currently carries clinical signal support. Linked drugs include APILIMOD, APILIMOD MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 1-phosphatidylinositol 3-phosphate 5-kinase as ChEMBL target CHEMBL1938222, mapped to UniProt Q9Y2I7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
1-phosphatidylinositol 3-phosphate 5-kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1938222
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9Y2I7
1-phosphatidylinositol 3-phosphate 5-kinase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 1-phosphatidylinositol 3-phosphate 5-kinase is the right protein anchor across sources, using UniProt Q9Y2I7 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Crohn's disease is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label1-phosphatidylinositol 3-phosphate 5-kinase
UniProt AccessionQ9Y2I7
Component TypeProtein
Sequence Length2098 aa

1-phosphatidylinositol 3-phosphate 5-kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as 1-phosphatidylinositol 3-phosphate 5-kinase, mapped to UniProt Q9Y2I7. Sequence length is 2098 aa.

Mapped IDQ9Y2I7
Review name1-phosphatidylinositol 3-phosphate 5-kinase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

1-phosphatidylinositol 3-phosphate 5-kinase shows clinical signal disease relevance led by Crohn's disease. 3 more disease programs remain visible in the same review block.

Clinical signal Phase II
Crohn's disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugAPILIMOD
Linked drugAPILIMOD MESYLATE
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugAPILIMOD
Clinical signal Phase II
rheumatoid arthritis
1 linked drug · 1 direct · 1 efficacy
Linked drugAPILIMOD MESYLATE
Clinical signal Phase I
common variable immunodeficiency
1 linked drug · 1 direct · 1 efficacy
Linked drugAPILIMOD
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Crohn's disease because it currently carries clinical signal support. Linked drugs include APILIMOD, APILIMOD MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCrohn's disease
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase II
Assay Mix

Activity Type Distribution

IC50105.0
EC501.0
KD69.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4297643 10.12 Kd 0.075 Clinical
CHEMBL4297643 9.51 IC50 0.309 Clinical
CHEMBL5572490 9.33 Kd 0.47 Preclinical
CHEMBL2178735 9.09 IC50 0.82 Preclinical
CHEMBL5555919 9.04 Kd 0.91 Preclinical
CHEMBL4303292 8.92 IC50 1.19 Preclinical
CHEMBL5568998 8.78 Kd 1.65 Preclinical
CHEMBL5189479 8.74 IC50 1.8 Preclinical
CHEMBL5557909 8.74 IC50 1.8 Preclinical
CHEMBL5193848 8.72 IC50 1.9 Preclinical
Distribution

pChEMBL Value Distribution

7
5.0
10
5.5
12
6.0
11
6.5
19
7.0
15
7.5
33
8.0
9
8.5
3
9.0
2
9.5
pChEMBL
Assay Landscape

Assay Landscape

97
Total Assays
92
Tested Compounds
2
Assay Types
Binding — 96 assays, 92 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 38 37 7.0
cell-based format 26 49 7.3
assay format 20 5 7.3
subcellular format 12 1 7.8
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine